1 min read
Add as a preferred source on Google

NervGen Pharma’s Net Loss Rises 36% to C$6.4 Million

Research and development expenses rose 84% to C$7.9 million, while general and administrative expenses increased 154% to C$3.3 million.

Three glass flasks sit at different fill levels on a steel bench / TokenPost.ai
Three glass flasks sit at different fill levels on a steel bench / TokenPost.ai

NervGen Pharma Corp. (NGEN) posted a C$6.4 million net loss, up 36% year over year, alongside sharp increases in research and administrative expenses, while diluted loss per share fell to C$0.06.

Research and development expenses climbed 84% to C$7.9 million. General and administrative expenses increased 154% to C$3.3 million.

Diluted loss per share was C$0.06, compared with C$0.07 a year earlier.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…